<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866709</url>
  </required_header>
  <id_info>
    <org_study_id>SPS-001</org_study_id>
    <nct_id>NCT01866709</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia</brief_title>
  <official_title>A Phase 4, Single-center, Prospective, Double-blind, Placebo-controlled, Randomized Study to Investigate the Safety and Efficacy of Sodium Polystyrene Sulfonate (SPS) in Subjects With Hyperkalemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ZS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ZS Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that SPS is more effective than placebo control (alternative hypothesis)&#xD;
      in lowering i-STAT potassium levels in subjects with i-STAT potassium levels between 5.0 -&#xD;
      6.5 mmol/l versus no difference between SPS and placebo control (null hypothesis).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with mild to moderate hyperkalemia (i-STAT potassium levels between 5.0-6.5 mmol/l,&#xD;
      inclusive) will be randomized 1:1 in a double-blind fashion to receive placebo or SPS (15g),&#xD;
      administered tid with meals for 48 hours. Subjects will come back to the clinic on Study Day&#xD;
      9 for an End of Study (EOS) visit. Adverse experiences will be recorded.&#xD;
&#xD;
      Blood potassium levels will be evaluated by both i-STAT and the Local Laboratory prior to the&#xD;
      first dose on Study Days 1 and 2, 1, 2, and 4 hours after the first dose on Study Day 1, 1&#xD;
      and 4 hours after the first dose on Study Day 2 and prior to breakfast on Study Day 3, after&#xD;
      48 hours of treatment.&#xD;
&#xD;
      Subjects who have i-STAT potassium levels &gt; 6.5 mmol/l on Study Day 1 at the 4 hour post Dose&#xD;
      1 time point will be withdrawn from the study and will receive standard of care. If the&#xD;
      i-STAT potassium value is between 6.1 and 6.5 mmol/l at the 4-hour post Dose 1 draw, subjects&#xD;
      will be kept in the clinic for another 90 minutes post Dose 2 and another blood draw will be&#xD;
      taken and an ECG will be performed. If the i-STAT potassium level is ≥ 6.2 mmol/l at this&#xD;
      time point, the subject will be discontinued from the study and standard of care will be&#xD;
      instituted. If the i-STAT potassium level is &lt; 6.2 mmol/l, and the ECG does not show any of&#xD;
      the ECG withdrawal criteria (see below), the subject will continue in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Risk/benefit determination showed study revealed negative safety issues.&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Potassium Levels From Baseline After Administration of Sodium Polystyrene Sulfonate (SPS) Three Times a Day Without Co-administration of Sorbitol; Determine Incidence of Adverse Events.</measure>
    <time_frame>First 48 hours</time_frame>
    <description>To perform a controlled evaluation of the safety and efficacy of 15g of SPS administered 3 times daily for 48 hours (6 doses) in patients with hyperkalemia (serum potassium levels between 5.0 - 6.5 mmol/l) at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Sodium, Magnesium, Calcium Levels From Baseline After Administration of SPS.</measure>
    <time_frame>First 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Sodium Polystyrene Sulfonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silicified microcrystalline cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium polystyrene sulfonate</intervention_name>
    <description>Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.</description>
    <arm_group_label>Sodium Polystyrene Sulfonate</arm_group_label>
    <other_name>SPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silicified microcrystalline cellulose</intervention_name>
    <description>Oral suspension in water of placebo administered three times (tid) daily for 48 hours.</description>
    <arm_group_label>Silicified microcrystalline cellulose</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent.&#xD;
&#xD;
          -  Over 18 years of age.&#xD;
&#xD;
          -  Mean i-STAT potassium values between 5.0 - 6.5 mmol/l inclusive, at screening (Study&#xD;
             Day 0).&#xD;
&#xD;
          -  Previous participation in Clinical ZS-002 or ZS-003 protocol(s). However, subjects&#xD;
             cannot be enrolled in this study until at least 30 days have elapsed from their last&#xD;
             dose in study ZS-003.&#xD;
&#xD;
          -  Ability to have repeated blood draws or effective venous catheterization.&#xD;
&#xD;
          -  Women of childbearing potential must be using two forms of medically acceptable&#xD;
             contraception (at least one barrier method) and have a negative pregnancy test at&#xD;
             screening.&#xD;
&#xD;
        Women who are surgically sterile or those who are post-menopausal for at least 2 years are&#xD;
        not considered to be of child-bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed&#xD;
             blood specimen, severe leukocytosis or thrombocytosis.&#xD;
&#xD;
          -  Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for&#xD;
             hyperammonemia within the last 7 days.&#xD;
&#xD;
          -  Subjects treated with resins (such as Sevelamer acetate), calcium acetate, calcium&#xD;
             carbonate, or lanthanum carbonate, within the last 7 days.&#xD;
&#xD;
          -  Subjects treated with Sodium Polystyrene Sulfonate (SPS; e.g. Kayexalate®) or ZS&#xD;
             (microporous, fractionated, protonated zirconium silicate) within the last 30 days.&#xD;
&#xD;
          -  Subjects with a life expectancy of less than 3 months.&#xD;
&#xD;
          -  Subjects who are HIV positive.&#xD;
&#xD;
          -  Subjects who are severely physically or mentally incapacitated and who in the opinion&#xD;
             of investigator are unable to perform the subjects' tasks associated with the&#xD;
             protocol.&#xD;
&#xD;
          -  Women who are pregnant, lactating, or planning to become pregnant.&#xD;
&#xD;
          -  Subjects with diabetic ketoacidosis.&#xD;
&#xD;
          -  Presence of any condition which, in the opinion of the investigator, places the&#xD;
             subject at undue risk or potentially jeopardizes the quality of the data to be&#xD;
             generated.&#xD;
&#xD;
          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.&#xD;
&#xD;
          -  Previous treatment with SPS.&#xD;
&#xD;
          -  Treatment with a drug or device within the last 30 days that has not received&#xD;
             regulatory approval at the time of study entry.&#xD;
&#xD;
          -  Subjects with cardiac arrhythmias that require immediate treatment.&#xD;
&#xD;
          -  Subjects on insulin where a stable dose has not yet been established.*&#xD;
&#xD;
          -  Subjects on dialysis. * Subjects on stable insulin or insulin analogues can be&#xD;
             enrolled. Subjects who have been on the same insulin dose and regimen for &gt; 14 days&#xD;
             are considered stable. Whenever possible, all blood draws collected prior to meals&#xD;
             should be collected prior to insulin/insulin analogue treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Rasmussen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ZS Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>May 28, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <results_first_submitted>August 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2014</results_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polystyrene sulfonic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sodium Polystyrene Sulfonate</title>
          <description>Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.&#xD;
Enrollment: Assessed for eligibility (n= 36 )&#xD;
Excluded (n= 4)&#xD;
Not meeting inclusion criteria (n= 4 )&#xD;
Declined to participate (n= 0)&#xD;
Other reasons (n= 0 )&#xD;
Randomized (n= 32 )&#xD;
Allocated to intervention (n= 15 ): ACTIVE&#xD;
Received allocated intervention (n= 15)&#xD;
Did not receive allocated intervention (give reasons) (n= 0 )&#xD;
Lost to follow-up (give reasons) (n= 0 )&#xD;
Discontinued intervention before study terminated (n= 1): non-serious adverse event&#xD;
Analyzed (n= 0)&#xD;
◻ Excluded from analysis (give reasons) (n= 32 study terminated early due to safety reasons)</description>
        </group>
        <group group_id="P2">
          <title>Silicified Microcrystalline Cellulose</title>
          <description>Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.&#xD;
Enrollment: Assessed for eligibility (n= 36 )&#xD;
Excluded (n= 4)&#xD;
Not meeting inclusion criteria (n= 4 )&#xD;
Declined to participate (n= 0)&#xD;
Other reasons (n= 0 )&#xD;
Randomized (n= 32 )&#xD;
Allocated to intervention (n= 17): PLACEBO&#xD;
Received allocated intervention (n= 17 )&#xD;
Did not receive allocated intervention (give reasons) (n= 0)&#xD;
Lost to follow-up (give reasons) (n= 0 )&#xD;
Analyzed (n= 0)&#xD;
◻ Excluded from analysis (give reasons) (n= 32 study terminated early due to safety reasons)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Mean i-STAT serum potassium values between 5.0 - 6.5 mmol/l inclusive at screening (Study Day 0) plus meeting inclusion/exclusion eligibility criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Sodium Polystyrene Sulfonate</title>
          <description>Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.&#xD;
Sodium polystyrene sulfonate (ACTIVE)&#xD;
Total Study Enrollment: Assessed for eligibility (n= 36 )&#xD;
Excluded (n= 4)&#xD;
Not meeting inclusion criteria (n= 4 )&#xD;
Declined to participate (n= 0)&#xD;
Other reasons (n= 0 )&#xD;
Total Randomized (n= 32 )&#xD;
Allocated to intervention (n= 15 ): ACTIVE&#xD;
Received allocated intervention (n= 15)&#xD;
Did not receive allocated intervention (give reasons) (n= 0 )&#xD;
Lost to follow-up (give reasons) (n= 0 )&#xD;
Discontinued intervention before study terminated (n= 1): non-serious adverse event&#xD;
Analysed (n= 0)&#xD;
◻ Excluded from analysis (give reasons) (n= 15): study terminated early due to safety reasons</description>
        </group>
        <group group_id="B2">
          <title>Silicified Microcrystalline Cellulose</title>
          <description>Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.&#xD;
Silicified microcrystalline cellulose (PLACEBO)&#xD;
Total Study Enrollment: Assessed for eligibility (n= 36 )&#xD;
Excluded (n= 4)&#xD;
Not meeting inclusion criteria (n= 4 )&#xD;
Declined to participate (n= 0)&#xD;
Other reasons (n= 0 )&#xD;
Total Randomized (n= 32 )&#xD;
Allocated to intervention (n= 17): PLACEBO&#xD;
Received allocated intervention (n= 17 )&#xD;
Did not receive allocated intervention (give reasons) (n= 0)&#xD;
Lost to follow-up (give reasons) (n= 0 )&#xD;
Discontinued intervention (give reasons) (n= 0)&#xD;
Analysed (n= 0)&#xD;
◻ Excluded from analysis (give reasons) (n= 17): study terminated early due to safety reasons</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" lower_limit="53" upper_limit="83"/>
                    <measurement group_id="B2" value="70.5" lower_limit="50" upper_limit="88"/>
                    <measurement group_id="B3" value="70.8" lower_limit="50" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Potassium Levels From Baseline After Administration of Sodium Polystyrene Sulfonate (SPS) Three Times a Day Without Co-administration of Sorbitol; Determine Incidence of Adverse Events.</title>
        <description>To perform a controlled evaluation of the safety and efficacy of 15g of SPS administered 3 times daily for 48 hours (6 doses) in patients with hyperkalemia (serum potassium levels between 5.0 - 6.5 mmol/l) at baseline.</description>
        <time_frame>First 48 hours</time_frame>
        <population>Study prematurely terminated for safety reasons; no statistical analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Polystyrene Sulfonate</title>
            <description>Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.&#xD;
Sodium polystyrene sulfonate</description>
          </group>
          <group group_id="O2">
            <title>Silicified Microcrystalline Cellulose</title>
            <description>Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.&#xD;
Silicified microcrystalline cellulose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Potassium Levels From Baseline After Administration of Sodium Polystyrene Sulfonate (SPS) Three Times a Day Without Co-administration of Sorbitol; Determine Incidence of Adverse Events.</title>
          <description>To perform a controlled evaluation of the safety and efficacy of 15g of SPS administered 3 times daily for 48 hours (6 doses) in patients with hyperkalemia (serum potassium levels between 5.0 - 6.5 mmol/l) at baseline.</description>
          <population>Study prematurely terminated for safety reasons; no statistical analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Sodium, Magnesium, Calcium Levels From Baseline After Administration of SPS.</title>
        <time_frame>First 48 hours</time_frame>
        <population>Study was prematurely terminated for safety reasons; no statistical analyses were conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Polystyrene Sulfonate</title>
            <description>Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.&#xD;
Sodium polystyrene sulfonate</description>
          </group>
          <group group_id="O2">
            <title>Silicified Microcrystalline Cellulose</title>
            <description>Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.&#xD;
Silicified microcrystalline cellulose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sodium, Magnesium, Calcium Levels From Baseline After Administration of SPS.</title>
          <population>Study was prematurely terminated for safety reasons; no statistical analyses were conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each study visit: Days 1, 2 and 9</time_frame>
      <desc>Participants were solicited for adverse events by systematic regular investigator assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sodium Polystyrene Sulfonate</title>
          <description>Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.&#xD;
Sodium polystyrene sulfonate (ACTIVE): Participants were solicited for adverse events at each study visit (i.e. Days 1, 2 and 9) by systematic regular investigator assessment.</description>
        </group>
        <group group_id="E2">
          <title>Silicified Microcrystalline Cellulose</title>
          <description>Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.&#xD;
Silicified microcrystalline cellulose (PLACEBO): Participants were solicited for adverse events at each study visit (i.e. Days 1, 2 and 9) by systematic regular investigator assessment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1E)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QT Interval</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.1E)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ST elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stomach cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI cannot publish any results related to the study without prior written approval of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the high frequency of adverse events in the SPS group, the independent Data Monitoring Committee (iDMC) recommended termination of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Henrik Rasmussen, MD, PhD</name_or_title>
      <organization>ZS Pharma, Inc</organization>
      <phone>443-699-5230</phone>
      <email>hrasmussen@zspharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

